Vonoprazan is a potassium competitive acid blocker, has shown potential used to treat acid reflux and eliminating Helicobacter pylori. Its enhanced anti-secretory action, quick action, and reduced anti-secretory variability make it a more suitable option than PPIs. However, many research is needed to fully understand the effects and its safety and tolerability profiles. The drug's effectiveness in treating reflux esophagitis is also reviewed. Due to the limits and unfulfilled therapeutic needs of proton pump inhibitors (PPIs), new medications also developed to address acid-related disorders and the elimination of H. pylori. Vonoprazan, a recently developed potassium-competitive acid blocker (P-CAB), demonstrated greater inhibition of stomach acid secretion. The effectiveness of vonoprazan in treating illnesses linked to acid reflux is reviewed in this paper, with an emphasis on its application in the elimination of Helicobacter pylori. Professional judgement: Vonoprazan demonstrated a few benefits over PPIs for the pharmacokinetic and pharmacodynamic characteristics of the drug: more powerful and extended suppression of acid secretion, quick commencement of action without the need for acid activation and precise dosing time, includes reduced anti-secretory variability and improved acid regulation at night. According to recent research, vonoprazan's enhanced anti-secretory action may make it a more suitable option than PPIs for treating reflux esophagitis and eliminating Helicobacter pylori. Furthermore, vonoprazan has good safety and tolerability profiles, albeit more extensive research is needed to fully understand its effects.
